Company intelligence / Profile preview

Oxford Gene Technology

Oxford, United Kingdom

Ownership: Private
Development stage: Other

Overview

Oxford Gene Technology (OGT) is a leading provider of genomics and molecular diagnostic solutions (like FISH, microarray, and NGS panels) for research and clinical laboratories. Acquired by Sysmex in June 2017, OGT's key product brands include CytoCell, CytoSure, and SureSeq, focusing on the identification of genetic abnormalities, particularly in cancer and inherited disease contexts. Founded by Professor Sir Edwin Southern in 1995, OGT works internationally and partners with researchers and clinicians in over 60 countries.

Therapeutic areas: OncologyRare Diseases
Modalities: MicroarrayFluorescence in situ hybridisationNext generation sequencing
Industry: Molecular Diagnostics

Partnerships

Sysmex

Beyond the preview

Go deeper on Oxford Gene Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oxford Gene Technology.

Explore the full profile